NASDAQ · ATRA
Healthcare · Biotechnology
$9.37
Down-$0.38 (-3.90%)
Updated Oct 8, 2026, 4:27 AM
SID Score
5.2/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · ATRA
1M range · 21 trading sessions · Daily adjusted prices
Prices through Oct 7, 2026
ATRA closed at $9.37 after 21 trading sessions, down 5.45% for the selected period.
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 7, 2026 | $9.62 | $9.7499 | $9.37 | $9.37 | 11.45K |
| Oct 6, 2026 | $9.41 | $9.79 | $9.05 | $9.75 | 47.6K |
| Oct 5, 2026 | $9.59 | $9.63 | $8.95 | $9.40 | 39.32K |
| Oct 2, 2026 | $8.46 | $9.675 | $8.25 | $9.48 | 85.75K |
| Oct 1, 2026 | $8.73 | $9.20 | $8.23 | $8.46 | 90.93K |
| Sep 30, 2026 | $8.08 | $8.7099 | $7.83 | $8.50 | 29.3K |
| Sep 29, 2026 | $8.33 | $8.8212 | $7.89 | $8.05 | 56.45K |
| Sep 28, 2026 | $8.69 | $8.705 | $8.3361 | $8.37 | 23.53K |
| Sep 25, 2026 | $8.60 | $8.99 | $8.535 | $8.81 | 31.2K |
| Sep 24, 2026 | $8.60 | $8.86 | $8.33 | $8.54 | 20.78K |
| Sep 23, 2026 | $8.92 | $8.95 | $8.40 | $8.56 | 40.47K |
| Sep 22, 2026 | $9.30 | $9.60 | $8.93 | $8.93 | 27.27K |
| Sep 21, 2026 | $9.69 | $9.92 | $9.30 | $9.38 | 29.67K |
| Sep 18, 2026 | $9.73 | $10.19 | $9.60 | $9.69 | 37.77K |
| Sep 17, 2026 | $10.28 | $10.28 | $9.41 | $9.71 | 26.42K |
| Sep 16, 2026 | $9.50 | $10.37 | $9.07 | $10.11 | 116.75K |
| Sep 15, 2026 | $9.21 | $9.88 | $8.92 | $9.44 | 56.06K |
| Sep 14, 2026 | $9.09 | $9.71 | $9.07 | $9.25 | 50.85K |
| Sep 11, 2026 | $10.00 | $10.00 | $9.38 | $9.38 | 16.03K |
| Sep 10, 2026 | $9.94 | $9.94 | $9.52 | $9.89 | 23.21K |
| Sep 9, 2026 | $10.27 | $10.43 | $9.76 | $9.91 | 68.51K |
The latest Smart Investors Daily articles mentioning ATRA.
Company
Market Activity
Research & News
ATRA research
Company profile and research snapshot.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| May 18, 2026 | Freedom Broker | Hold | — |
| May 8, 2026 | Canaccord Genuity | Buy | — |
| Jan 13, 2026 | Canaccord Genuity | Hold | — |
| Dec 19, 2025 | Canaccord Genuity | Buy | — |
| Mar 11, 2025 | Canaccord Genuity | Buy | — |
No generated briefing is available yet.
Finnhub · May 17, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
Finnhub · May 15, 2026
Faruqi & Faruqi, LLP, a leading national securities law firm, is investigating potential claims against Atara...
Finnhub · May 12, 2026
Atara Biotherapeutics Inc: Atara Biotherapeutics Inc - may offer up to $79.27 million in common stock as of May 12, 2026 - SEC filing...
Benzinga · May 12, 2026
Atara Biotherapeutics (NASDAQ:ATRA) reported quarterly losses of $(0.29) per share which beat the analyst consensus estimate of $(0.41) by 27.5 percent. This is a 108.29 percent decrease over earnings of $3.50 per share
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning ATRA.
